Background: An unknown location hampers removal of pancreatic tumours. We studied the effects of enzyme inhibitors on the uptake of 6-[
Background
Due to late diagnosis and lack of effective treatment, pancreatic adenocarcinoma has the worst prognosis of all of the gastrointestinal cancers [1] . Surgery is a possible curative approach if the cancer is detected early, but the exact location of the tumour is often difficult to determine. Current anatomy-based imaging procedures detect only indirect signs of invasive tumour growth such as pancreatic mass or ductal abnormalities. Therefore, there is a need for better functional imaging tools for the detection and localisation of pancreatic cancer.
The most frequently used positron emission tomography (PET) tracer for tumour imaging is the glucose analogue, 2-deoxy-2-[ [2, 3] . For pancreatic cancer, [ 18 F]FDG has been useful in the evaluation of indeterminate pancreatic masses, staging of pancreatic carcinoma, detection of metastatic disease and differentiation of viable tumours from posttherapeutic processes like necrosis or scar tissue [4, 5] . However, the diagnostic value of [ [2, 6] .
Investigation of the functional activity of the dopaminergic system is increasingly used in the evaluation of tumours of islet cell origin [7] [8] [9] [10] [11] [12] . 6-[ [7, 8] . At present, the imaging of the pancreas using [ 18 F]FDOPA is focused on the neuroendocrine nature of pancreatic cells [13] ; however, the exocrine pancreas also contains dopamine [14] . According to previous immunohistochemical studies, exocrine cells can take up amine precursors such as L-DOPA, transport them across the cell membrane, convert them into dopamine by aromatic L-amino-acid decarboxylase (AADC) and store them in vesicles [15] [16] [17] .
In the periphery, [ [21] . Carbidopa also improves imaging of neuroendocrine tumours of the pancreas [22, 23] . However, recent studies have shown that the use of enzyme inhibitors for other cancers of the pancreas, such as islet cell tumours, β cell hyperplasias and insulinomas, may hamper pancreatic uptake of [ 18 F]FDOPA in addition to hindering its uptake by tumour cells [24] . 
Methods

Cell culture
Human ductal pancreatic adenocarcinoma cells (BxPC3 cells) were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated foetal calf serum and 2 mM of Lglutamine (all from Sigma-Aldrich Chemicals, Steinheim, Germany). The cells were maintained at 37°C in a humid atmosphere with 5% CO 2 . For orthotopic inoculation, the cells were trypsinised and suspended in Matrigel (BD Biosciences, San Jose, CA, USA) at a concentration of 10 6 cells/ mL and stored on ice. The viability of the cells was confirmed by trypan blue staining before and after inoculation.
Orthotopic tumours
Five-week-old male immunodeficient nude mice (Athymic nude/nu Foxn1 mice, Harlan, The Netherlands) were used in this study. Animals were treated with analgesics (Temgesic W 0.1 mg/kg, mouse body weight 23.2 ± 1.9 g) and anaesthetised by isoflurane inhalation (3%, 200 mL/ min). After laparotomy, 30 μL of cell suspension (3 × 10 4 cells) was inoculated into the pancreatic body of the mice (n = 26). Mice were weighed twice per week, and their welfare was evaluated daily. Sham-operated nude mice (n = 22), which were inoculated only with Matrigel, were used as controls. Animals were sacrificed 35 Table 1 . Mice were treated with carbidopa (0.5 mg 0.25% carbomethyl cellulose sodium salt, SigmaAldrich Chemicals; n = 6 + 6, sham-operated and BxPC3), Ro-41-0960 (0.9 mg/150 μL in ethanol; n = 2 + 5), clorgyline (0.3 mg 0.25% carbomethyl cellulose sodium salt; n = 2 + 5) or a combination of Ro-41-0960 and clorgyline (n = 6 + 5). All enzyme inhibitors were purchased from Sigma-Aldrich Chemicals. Animals treated with 0.9% NaCl were used as controls (n = 6 + 5). Mice were either sacrificed for ex vivo analysis 10 min after injection of [ 
Small-animal PET/CT and image analysis
Six weeks after orthotopic inoculation of the BxPC3 cells, the uptake of [ The whole pancreata were exposed. Tumours were not dissected from the pancreata. Tumour volumes were calculated according to the formula π/6(
, where d 1 to d 3 are perpendicular tumour diameters (mm) [30] . The absolute 18 F radioactivity uptake was determined from blood and selected abdominal tissues (Table 1 ) using a gamma counter (3 in × 3 in NaI (Tl) crystal, Bicron 3 MW3/3P; Bicron Inc., Newbury, OH, USA) at 10 min after the injection of [ 18 F]DOPA. Tissues were weighed, counted for radioactivity and corrected for background radioactivity and radioactivity decay. The quantity of radioactivity was expressed as the percentage of injected dose per gram of tissue (% ID/g). In order to determine the intratumoural biodistribution pattern of 18 F radioactivity, tumours were rapidly frozen in dry ice/isopentane and cut with a cryomicrotome into 20-μm sections. Tissue sections were exposed to an imaging plate (Fuji BAS TR2025, Fuji Photo Film Co., Tokyo, Japan) for 4 ± 0.5 h. The spatial distribution of radioactivity was recorded with a phosphoimaging device (Fuji BAS 5000, with a resolution of 25 μm). Images were analysed for count density (photostimulated luminescence per unit area) with the Aida image analysis software (v. 4.22, Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany). The same tissue sections were stained with haematoxyline/eosin for histological analysis. Whole-tumour images were produced using a Zeiss AxioVert 200 M microscope with AxioCam MRc camera and the MosaiX option of AxioVision [31, 32] were used to identify retention times (Rt) in a similar chromatographic system.
Statistical analysis
The mean weight of the sham-operated pancreas and pancreas with a tumour was compared with a two-sample t test. Radioactivity (ratios to non-target tissues and autoradiography) measurements were analysed using a twoway analysis of variance. Models included the main effects of pretreatment (vehicle, carbidopa and COMT + MAO-A) and group (sham-operated and tumour-bearing animals). In further pairwise comparisons between pretreatments, the Tukey adjustment method was used. Interaction between pretreatment and group was also tested. Due to positively skewed distributions, log-transformed values were used in statistical analyses. SAS System for Windows was used in statistical computations (v. 9.2, SAS Institute Inc., Cary, NC, USA); p values less than 0.05 were considered as statistically significant.
Results and discussion
Tumour characterisation and ex vivo biodistribution of
No differences were detected between the weights of sham-operated and tumour-bearing mice (data not shown). No signs of cachexia were detected, which indicates that the tumours were not very large (data not shown). The tumour occurrence was 100%, and the mean tumour volume was 50 ± 40 mm 3 at 35 days after tumour cell inoculation and 760 ± 1,300 mm 3 at 42 days after tumour cell inoculation. The mean weight of the sham-operated pancreas was 0.18 ± 0.03 g, while the weight of the pancreas with a tumour at 35 and 42 days after inoculation was 0.27 ± 0.08 g (p < 0.001 vs. shamoperated) and 0.73 ± 0.97 g (p < 0.001 vs. sham-operated), respectively. As expected, the weight of the pancreata increased in tumour-bearing mice compared with the sham-operated mice.
The ex vivo distribution of [ 18 F]FDOPA-derived activity was expressed as percentage of injected dose per gram of tissue ( Table 1 ). The highest amount of radioactivity was found in the pancreas (including BxPC3 tumours, as applicable), liver, kidneys and small intestine when vehicle alone was used as pretreatment (Table 1) . Interestingly, the uptake was twofold higher in shamoperated pancreata than in tumour-bearing pancreata ( Table 1) . Carbidopa pretreatment increased the uptake in the pancreas in sham-operated and tumour-bearing animals three-and fourfold, respectively, compared with vehicle pretreatment. However, no differences were detected between carbidopa pretreated sham-operated and tumourbearing animals ( Table 1 ). Combined administration of COMT and MAO-A inhibitors doubled the uptake of 18 F radioactivity by the pancreata of sham-operated animals compared with vehicle pretreated animals. The 18 F radioactivity uptake in the pancreas was threefold lower in tumour-bearing animals that received COMT + MAO-Ainhibitors in comparison with sham-operated animals with the same pretreatment. No major between-mice differences in other studied organs were detected. Administration of the MAO-A or COMT inhibitors alone had no effect on 18 F radioactivity uptake (Table 1) , and therefore, carbidopa and COMT + MAO-A inhibitors were selected for further study. Figure 2 Ratios to non-target tissues (pancreas-to-muscle and pancreas-to-liver) from ex vivo radioactivity measurements (% ID/g). These were measured after [ 18 F]FDOPA injection. Significant differences were detected between sham-operated and BxPC3 tumour-bearing pancreata (pretreatment adjusted p < 0.001 in pancreas-to-muscle and pretreatment adjusted p < 0.05 in pancreas-to -liver ratios), but pretreatment had no effect on these differences (pretreatment × group interaction effect, p = 0.245 in pancreas-to -muscle and p = 0.612 in pancreas-to-liver ratios). Carbidopa pretreatment increased uptake in the pancreata of both shamoperated and tumour-bearing mice compared with vehicle-treated mice (group adjusted p < 0.05 in pancreas-to-muscle and group adjusted p < 0.001 in pancreas-to-liver ratios). The numbers of mice exposed to vehicle, carbidopa and COMT + MAO-A inhibitors were 6, 5 and 4 for sham-operated animals, respectively, and 5, 7 and 4 for tumour-bearing animals, respectively. Values are shown as mean and standard error.
Target-to-non-target ratios (pancreas-to-muscle and pancreas-to-liver) were calculated based on measured radioactivities (% ID/g), and they are presented in Figure 2 . Our data revealed significant differences between shamoperated and BxPC3 tumour-bearing pancreata (pretreatment adjusted p < 0.0001 in pancreas-to-muscle and p = 0.026 in pancreas-to-liver ratios). However, these differences were not dependent on the used pretreatment (pretreatment × group interaction effect, p = 0.245 in pancreas-to-muscle and p = 0.612 in pancreas-to-liver ratios). Carbidopa pretreatment increased the uptake in the pancreata in both sham-operated and tumour-bearing mice compared with vehicle treatment (group adjusted p = 0.037 in pancreas-to-muscle and p < 0.0001 in pancreas-to-liver ratios), but the difference between the sham-operated and tumour-bearing mice was not high enough to separate the healthy pancreas from the tumourbearing pancreas (Figure 2 ). Pretreatment with COMT + MAO-A inhibitors increased the ratio further, especially the pancreas-to-muscle ratio, but due to the small number of observations and the larger variance in a measured radioactivity in the samples, the differences did not achieve any statistical significance (p = 0.133 in pancreas-to-muscle and p = 0.386 in pancreas-to-liver ratios, Figure 2 ). (Figure 3b) . However, the uptake in the healthy part of the pancreas increased after pretreatment with COMT + MAO-A inhibitors (Figure 3c,d) . Based on 20 min of dynamic scanning, the peak and plateau radioactivities in the pancreas were reached within 5 min (Figure 3d ). The time-activity curves of the pancreata showed similar dynamics regardless of pretreatment (vehicle vs. COMT + MAO-A inhibitors, Figure 3d ) or tumour status (sham-operated vs. tumour-bearing mice, Figure 3d ).
Autoradiography identifies low [
18 F]FDOPA uptake in the tumour part of the pancreas
Intratumoural distribution of 18 F radioactivity was determined by digital autoradiography. Histological images of the haematoxylin/eosin-stained slices were combined with autoradiography, and the tumour outlines were drawn. In intrapancreatic comparison between the healthy pancreas and the tumour, radioactivity uptake was on average tenfold lower in tumour areas than in the healthy pancreas following pretreatments with vehicle or carbidopa. This uptake was fivefold lower in tumours of COMT + MAO-A pretreated pancreata (Figure 4a,b,c,d ). In healthy areas of the pancreas, uptake was dependent on pretreatment. The uptake was uniform in the pancreata of vehicle-or carbidopa-treated mice (Figure 4a,b) , while pretreatment with COMT + MAO-A inhibitors led to a 2.4-fold increase in uptake in the head of the pancreas compared with uptake in the tail of the pancreas (Figure 4c) . A representative histological image indicates tumour growth in the body of the pancreas of mouse pretreated with COMT + MAO-A inhibitors (Figure 4d) . After normalising the uptake with the amount of the injected radioactivity for each pancreas, pretreatment had an effect on the difference between sham-operated and tumour-bearing animals (pretreatment × group interaction effect p = 0.039, Figure 4e ). Lower uptake was detected in tumour-bearing pancreata compared with sham-operated pancreata in vehicle (p = 0.016) and COMT + MAO-A inhibitor-treated (p = 0.002) animals. In carbidopa-treated mice, no significant difference was detected between sham-operated and tumour-bearing animals (p = 0.733). These observations were in accordance with ex vivo biodistribution data (Table 1 and Figure 2 ) as well as PET/CT data ( Figure 3 ).
Pretreatment affects [ 18 F]FDOPA metabolism in pancreas
Metabolites were analysed in pancreatic samples of shamoperated and tumour-bearing mice using HPLC. HPLC radiochromatograms from a radiometabolite study are shown in Figure 5 . Of the several radiolabelled metabolites of [ [7, [35] [36] [37] . The objective of this study was to investigate the usefulness of [ 18 F]FDOPA also in the imaging of pancreatic adenocarcinoma and to assess the possible benefits of clinically available, widely used enzyme inhibitors of catecholamine neurotransmitters.
PET/CT was used to visualise whole-body anatomical and functional information from the tumour-bearing mice. [21, 38] . In the present study, outlining of the pancreas improved, when the animals were treated with carbidopa or COMT and MAO-A inhibitors before [ Figure 5 ), which is easily transported to both tumour cells and pancreatic cells [39] . However, when COMT + MAO-A were inhibited, the main metabolite is [ Ex vivo distribution studies demonstrated major (twoto fourfold) differences in 
Conclusions
Our study indicates that pretreatment of mice with carbidopa increases [ 18 F]FDOPA uptake in the pancreas and therefore facilitates the localisation of the pancreas, but it also impairs the observer's ability to separate the healthy pancreas from the tumour because, in addition to exocrine pancreatic cells, tumour cells are also able to uptake [ 18 F]3-OMFD, which is the main metabolite after carbidopa administration. COMT + MAO-A inhibitors increased the 18 F radioactivity uptake in pancreatic tissue, while the uptake in tumours is poor due to the formation of [ 
